A free open access ebook is available upon publication. Learn more at www.luminosoa.org.
Capitalizing a Cure takes readers into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. But their sticker shock—the drug was dubbed "the $1,000-a-day pill"—intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy, science, and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued.
Roy's account moves between public and private labs, Wall Street and corporate boardrooms, public health meetings, and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures.
Capitalizing a Cure How Finance Controls the Price and Value of Medicines
The pandemic has created major supply chain challenges for publishers, manufacturers, warehousing facilities and shipping companies. Please allow for a minimum of 15 business days to receive your order. If you need your order sooner, consider purchasing from one of our retail partner links in the buying options. Thank you!